Blue Cross Blue Shield of North DakotaMedicaid · Prior Auth · Pharmacy · ND · Oncology, HematologyHigh impact
Pharmacy Policies Updates
Act
by Oct 1, 2025
Effective date
Oct 1, 2025
Identified
Jun 19, 2026
Summary
Blue Cross Blue Shield of North Dakota has updated multiple pharmacy prior authorization policies for specialty medications, with new requirements effective October 1, 2025 for Datopotamab deruxtecan-dlnk (Datroway) and revised policies for various oncology drugs effective November 1, 2025. These changes affect prior authorization criteria, step therapy requirements, and billing codes for high-cost specialty medications.
Get alerts when payers change rules like this one
We check Blue Cross Blue Shield of North Dakota and other payers every day and email you when a change matches your specialty and state.
01Billing team must update prior authorization requirements for Datopotamab deruxtecan-dlnk (Datroway) in billing system for Medicaid Expansion patients.
02By November 1, 2025: Update prior authorization policies for Bevacizumab, Exagamglogene autotemcel, Inebilizumab-cdon, Naxitamab, PD-1/PD-L1 blocking antibodies, and Tafasitamab-cxix.
03Review gateway portal at www.gatewaypa.com/policydisplay/52 for complete Commercial policy updates.
04Update billing codes and ICD-10 mappings in system.
If missed: Failure to obtain required prior authorizations will result in claim denials.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.